NCT00712894

Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction

Reversal of No-reflow/Slow-flow During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction--a Prospective Randomized Study Comparing Intracoronary Infusion of Diltiazem, Verapamil and Nitroglycerin

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of three different vasodilators including diltiazem, verapamil and nitroglycerin for reversal of no-reflow/slow-flow during direct percutaneous coronary intervention for acute myocardial infarction.

Detailed description

No-reflow/slow-flow is a frequent observation during direct PCI for AMI and associated with a poor clinical outcome. The present pharmacological management involves the use of different vasodilators including nitrates, verapamil, adenosine and nicorandil. But no randomized trial has been conducted to assess any of these agents, or to determine the appropriate dosage. This prospective randomized study aimed to confirm favorable effects of diltiazem on no-reflow/slow-flow during direct PCI for AMI compared with verapamil and nitroglycerin.

Conditions

• Acute Myocardial Infarction
• Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	Diltiazem	Intracoronary Infusion 400-2000ug
DRUG	Verapamil	Intracoronary Infusion 200-1000ug
DRUG	Nitroglycerin	Intracoronary Infusion 200-1000ug

Timeline

• Start date: 2006-12-01
• Primary completion: 2009-04-01
• Completion: 2009-08-01
• First posted: 2008-07-10
• Last updated: 2012-09-24

Locations

1 site across 1 country: China